Connor, Clark & Lunn Investment Management Ltd. Astria Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $18.8 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024
SELL
$4.42 - $8.06 $126,350 - $230,403
-28,586 Reduced 67.95%
13,484 $103,000
Q3 2023

Nov 13, 2023
SELL
$6.89 - $9.86 $72,985 - $104,446
-10,593 Reduced 20.11%
42,070 $313,000
Q2 2023

Aug 10, 2023
BUY
$8.33 - $13.72 $126,149 - $207,775
15,144 Added 40.36%
52,663 $438,000
Q1 2023

May 09, 2023
BUY
$11.2 - $15.79 $222,600 - $313,826
19,875 Added 112.64%
37,519 $499,000
Q4 2022

Feb 10, 2023
BUY
$7.44 - $14.89 $131,271 - $262,719
17,644 New
17,644 $262,000

Others Institutions Holding ATXS

# of Institutions
107
Shares Held
48.6M
Call Options Held
48K
Put Options Held
9.3K
View Full List

About Astria Therapeutics, Inc.

ATXS Quotes by TradingView
  • Ticker ATXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,178,000
  • Market Cap $135M
  • Description
  • Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...
More about ATXS
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email